ES2133380T3 - Composiciones farmaceuticas que contienen glicosidos de antraciclina unidos a derivados polimeros, y su procedimiento de preparacion. - Google Patents

Composiciones farmaceuticas que contienen glicosidos de antraciclina unidos a derivados polimeros, y su procedimiento de preparacion.

Info

Publication number
ES2133380T3
ES2133380T3 ES93902124T ES93902124T ES2133380T3 ES 2133380 T3 ES2133380 T3 ES 2133380T3 ES 93902124 T ES93902124 T ES 93902124T ES 93902124 T ES93902124 T ES 93902124T ES 2133380 T3 ES2133380 T3 ES 2133380T3
Authority
ES
Spain
Prior art keywords
anthracicline
pharmaceutical compositions
compositions containing
preparation procedure
polymer derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93902124T
Other languages
English (en)
Inventor
Marco Adami
Roberto Magrini
Paolo Maranghi
Antonino Suarato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Application granted granted Critical
Publication of ES2133380T3 publication Critical patent/ES2133380T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTA UNA COMPOSICION LIOFILIZADA QUE COMPRENDE (A) UN CONJUGADO QUE COMPRENDE UN COPOLIMERO BASADO EN METACRILAMIDO DE N-ALQUIL Y UN GLICOSIDO DE ANTRACICLINA ENLAZADO A TRAVES DE SEPARADOR PEPTIDO AL COPOLIMERO Y (B) UN AGENTE COSOLUBILIZANTE, LA COMPOSICION PUEDE CONTENER OPCIONALMENTE (C) UN MATERIAL DE RELLENO. TAMBIEN OPCIONALMENTE, UNA MOLECULA PUEDE ESTAR UNIDA AL COPOLIMERO DEL CONJUGADO POR MEDIO DE UN SEPARADOR PEPTIDO. ASIMISMO SE PRESENTA UNA SOLUCION INYECTABLE DE CONJUGADO QUE SE OBTIENE MEDIANTE LA RECONSTITUCION DE LA COMPOSICION LIOFILIZADA.
ES93902124T 1992-01-07 1992-12-21 Composiciones farmaceuticas que contienen glicosidos de antraciclina unidos a derivados polimeros, y su procedimiento de preparacion. Expired - Lifetime ES2133380T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929200247A GB9200247D0 (en) 1992-01-07 1992-01-07 Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation

Publications (1)

Publication Number Publication Date
ES2133380T3 true ES2133380T3 (es) 1999-09-16

Family

ID=10708214

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93902124T Expired - Lifetime ES2133380T3 (es) 1992-01-07 1992-12-21 Composiciones farmaceuticas que contienen glicosidos de antraciclina unidos a derivados polimeros, y su procedimiento de preparacion.

Country Status (22)

Country Link
US (1) US6245358B1 (es)
EP (1) EP0574571B1 (es)
JP (1) JPH06505755A (es)
KR (1) KR100290222B1 (es)
AT (1) ATE179618T1 (es)
AU (1) AU666513B2 (es)
CA (1) CA2105466A1 (es)
DE (1) DE69229109T2 (es)
DK (1) DK0574571T3 (es)
ES (1) ES2133380T3 (es)
FI (1) FI933853A (es)
GB (1) GB9200247D0 (es)
GR (1) GR3030633T3 (es)
HU (2) HU217806B (es)
IL (1) IL104256A (es)
MX (1) MX9207605A (es)
NZ (1) NZ246577A (es)
RU (1) RU2118171C1 (es)
TW (1) TW218847B (es)
UA (1) UA32522C2 (es)
WO (1) WO1993013804A1 (es)
ZA (1) ZA9210049B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
WO1998047496A2 (en) * 1997-04-18 1998-10-29 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US7314956B2 (en) 2001-08-08 2008-01-01 Vaxim, Inc. Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
WO2003017938A2 (en) * 2001-08-22 2003-03-06 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
EP1562546A1 (en) * 2002-10-25 2005-08-17 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
CN1774259B (zh) * 2003-01-14 2011-12-28 特瓦制药工业有限公司 治疗系统性红斑狼疮的肽的胃肠道外制剂
KR20070088447A (ko) * 2005-05-11 2007-08-29 시코르, 인크. 안정한 동결건조된 안트라사이클린 글리코시드
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
PL2121139T3 (pl) * 2007-01-16 2013-03-29 Bipar Sciences Inc Formulacje do leczenia raka
EP2222273A2 (en) * 2007-11-12 2010-09-01 Novartis AG Liquid compositions comprising valsartan
WO2009118754A2 (en) * 2008-03-28 2009-10-01 Astron Research Limited A process for preparing a stable lyophilized composition
EP2274017B1 (en) * 2008-04-30 2016-04-13 Ben Gurion University Of The Negev Research And Development Authority E-selectin specific vascular delivery systems
KR102239752B1 (ko) * 2019-12-11 2021-04-13 한국과학기술연구원 종양 특이적 약물복합체와 항pd-l1 항체를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS173846B1 (es) * 1974-04-23 1977-03-31
US4460560A (en) * 1982-06-18 1984-07-17 University Of Southern California Drug delivery by polymeric carriers
FR2561916B1 (fr) * 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
FR2583983B1 (fr) * 1985-06-07 1988-05-27 Centre Nat Rech Scient Nouvelles prodrogues macromoleculaires hydrosolubles, leur preparation et leur utilisation comme medicaments notamment antitumoraux et antiparasitaires
GB8519452D0 (en) * 1985-08-02 1985-09-11 Erba Farmitalia Injectable solutions
US4968742A (en) * 1987-11-09 1990-11-06 Miles Inc. Preparation of ligand-polymer conjugate having a controlled number of introduced ligands
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs

Also Published As

Publication number Publication date
RU2118171C1 (ru) 1998-08-27
EP0574571B1 (en) 1999-05-06
HUT74578A (en) 1997-01-28
MX9207605A (es) 1993-08-01
DE69229109D1 (de) 1999-06-10
IL104256A (en) 1997-02-18
CA2105466A1 (en) 1993-07-08
DE69229109T2 (de) 1999-08-26
EP0574571A1 (en) 1993-12-22
KR100290222B1 (ko) 2001-09-17
AU666513B2 (en) 1996-02-15
DK0574571T3 (da) 1999-11-01
GR3030633T3 (en) 1999-10-29
FI933853A0 (fi) 1993-09-03
HU217806B (hu) 2000-04-28
HU9302517D0 (en) 1993-12-28
IL104256A0 (en) 1993-05-13
UA32522C2 (uk) 2001-02-15
GB9200247D0 (en) 1992-02-26
JPH06505755A (ja) 1994-06-30
HU211636A9 (en) 1995-12-28
FI933853A (fi) 1993-09-03
ZA9210049B (en) 1993-10-06
ATE179618T1 (de) 1999-05-15
NZ246577A (en) 1996-03-26
US6245358B1 (en) 2001-06-12
AU3346893A (en) 1993-08-03
TW218847B (es) 1994-01-11
WO1993013804A1 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
ES2133380T3 (es) Composiciones farmaceuticas que contienen glicosidos de antraciclina unidos a derivados polimeros, y su procedimiento de preparacion.
SE8504945D0 (sv) Pharmaceutical compositions containing anthracycline glycosides
MX9203072A (es) Asialoglucoproteina-agente conjugado medicinal.
KR920700601A (ko) 피부투과 증진제 조성물
RU93055778A (ru) Фармацевтические композиции, содержащие антрациклиновые гликозиды, связанные с полимерным производным, и способ их получения
MX9303598A (es) Conjugados polimeros de taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
EA200000376A1 (ru) Полимерные производные камптотецинов
AU691476B2 (en) Injectable taxane derivative based compositions
ES2149340T3 (es) Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
ATE136792T1 (de) Zellmembran-mischungsmittel enthaltende molekularkonjugate
MY103365A (en) 4-demethoxy-4-amino-anthracyclines
IT1205978B (it) Derivati di dicloroanilina,composizioni farmaceutiche che li contengono e procedimento per produrli
RS49566B (sr) Kompozicije koje sadrže antifungicidno sredstvo i acetatni pufer
DE69322265T2 (de) Alkylthioalkylavermectine sind aktive antiparasitäre wirkstoffe
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
GR1002294B (el) Συνδυασμενο εμβολιο για streptococcus ομαδας β.
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
CA2504963A1 (en) Conjugates of tnf and a ligand of cd13 receptor in combination with interferon-gamma for treating cancer
UA42695C2 (uk) Полімерзв'язаний антрациклін, фармацевтична композиція та проміжна сполука
DE69624563D1 (de) Pharmazeutische zusammensetzung hergestellt durch zugabe eines geschmackstoff an einer wirkstoff
MY102186A (en) Antitumor anthracycline glycosides, their preparation intermediate thereof, and compositions and use thereof
PT1058544E (pt) Inibicao da actividade do tnf
AR031508A1 (es) Compuesto polisacarido con actividad inmunoestimulante
KR970032876A (ko) 간장질환 치료용 의약 조성물
SE8300324L (sv) Daunorubicin och doxorubicin-analoger, deras framstellning och anvendning

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19940628

FG2A Definitive protection

Ref document number: 574571

Country of ref document: ES